Diagnosis and Treatment Strategies in Patients With NSCLC With or Without EGFR Mutations.

AstraZeneca450 enrolled

Overview

The purpose of this trial is to compare the evolution of patients receiving first line treatment for locally advanced or metastatic lung cancer, taking into account if they were requested or not the EGFR mutation test as part of the diagnosis and treatment strategy. There is no assignment to any particular therapeutic strategy.

Study of cases and controls on diagnosis and treatment strategies in patients with NSCLC with or without EGFR mutations.

Study Type

OBSERVATIONAL

Enrollment

450

Conditions

Stage IIIB/IV Non-Small Cell Lung Cancer

Eligibility

Sex: ALLMin age: 18 Years

Medical Language ↔ Plain English

Inclusion Criteria: * Patients with confirmed diagnosis of lung adenocarcinoma, stage IIIb/IV. * Patients under 1st line treatment against lung adenocarcinoma. Exclusion Criteria: * Patients not having the information required by the protocol.

Locations (17)

Research Site

Bahía Blanca, Buenos Aires, Argentina

Research Site

Ciudad de Buenos Aires, Buenos Aires, Argentina

Research Site

Outcomes

Primary Outcomes

Disease free survival

Time frame: 12 months after the diagnosis of advanced disease

Overall Survival

Time frame: 12 months after the diagnosis of advanced disease

Number of hospitalizations

Time frame: 12 months after the diagnosis of advanced disease

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.